SubHero Banner
Text

Thymoglobulin® [anti-thymocyte globulin (rabbit)] – Expanded indication

April 24, 2017 – Sanofi announced the FDA approval of Thymoglobulin [anti-thymocyte globulin (rabbit)] injection, for the prophylaxis of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.

Download PDF